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ABSTRACT
Objectives: To determine the overtreatment and re-LEEP rates of see and treat strategy (S & T) in women who underwent  
S & T by LEEP and to identify the risk factors for overtreatment and surgical margin and/or endocervical curettage positivity.
Material and methods: A total of 800 patients who underwent S & T in Istanbul University Cerrahpasa Medical Faculty 
between June 2010 and June 2016 were retrospectively analyzed. 
Results: Overtreatment rate was found to be 46.6%, decreasing with higher grade of cervical smear abnormalities. Age 
more than 45, low grade of cervical cytologic abnormality and absence of glandular involvement were associated with 
higher overtreatment rates. The more advanced the histopathology, the more increased risk of surgical margin on LEEP and 
ECC positivity (p < 0.0001, for both). Glandular involvement was associated with both surgical margin and ECC positivity. 
Conclusions: S & T can be used in patients with high grade cytologic anomaly with an acceptable overtreatment rate. In 
addition, bigger pieces of specimens may need to be removed during LEEP in patients who have suspicious images of 
higher grade of abnormalities on colposcopy to reduce surgical margin or ECC positivity. When high rate of ECC positivity 
in patients with HSIL cytology is considered, we suggest performing ECC to every patients with HSIL.
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INTRODUCTION
Cervical cancer remains the most common gyneco-
logical cancer around the world [1]. Due to the fact that 
development of cervical carcinoma occurs over a long pe-
riod, which may permit an early diagnosis and treatment 
of precancerous cervical lesions, cytology-based screening 
programs have significantly reduced the incidence of the 
disease [2]. Women with an abnormal Pap smear result 
undergo colposcopic examination and colposcopic-guided 
biopsy, and, through this standard procedure, cervical can-
cer may be prevented [3]. In case of a suspicious finding for 
cervical intraepithelial neoplasia (CIN) 2+ on colposcopy, 
loop electrosurgical excision procedure (LEEP), a safe and 
effective treatment modality that is used in the removal of 
cervical dysplasia, can be offered to the patient instead of 
cervical biopsy for diagnosis and treatment of the disease. 
This option is referred to as the see and treat strategy (S & T). 
There are some advantages and disadvantages of these 
two options for the management of women with abnormal 
cytology results.
S & T has commonly been compared to the classical 
three step procedure involving colposcopy-guided biopsy 
followed by treatment of high grade lesions. The major 
concern of S & T is overtreatment, which is associated with 
increased morbidity and cost [4]. However, management 
based on colposcopy-guided biopsy may be insufficient to 
exclude CIN 2+. Some studies have reported that, even in 
experienced clinics, colposcopy-guided biopsy dismisses 
up to 30% of high grade cervical lesion [5]. In addition, S & T 
has been shown to decrease patient anxiety, number of 
medical visits, and travel cost [6]. It may also prevent patient 
dropout before treatment  [7]. Some studies have reported 
that up to 25% of patients in the three steps strategy did 
not return for their next visit [8].
The last WHO guideline on screening and treatment 
of cervical precancerous lesions recommended the use of 
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S & T in countries where an appropriate screening strategy 
with cytology followed by colposcopy is present in women 
with ASCUS or greater results [9]. LEEP has been found to 
be a feasible and safe treatment method. Re-LEEP is recom-
mended in the presence of positive surgical margin after 
first LEEP or positive endo-cervical curettage (ECC), as these 
are associated with significantly higher rates of persistence 
or recurrence [10]. 
The present study was aimed at the evaluation of S & T 
for women with abnormal cytology and suspicious finding(s) 
on colposcopy in the diagnosis and management of cervical 
pathology. In this present study, we investigated the rate of 
overtreatment according to different abnormal cytology 
results. The second purpose of this study was to evaluate 
the factors related to positive margin and evaluate the role 
and importance of ECC in S & T.
MATERIAL AND METHODS
After obtaining approval from the Ethics Committee of 
Istanbul University Cerrahpasa Medical Faculty, retrospec-
tive analysis of women who had undergone LEEP at the 
Division of Gynecologic Oncology of Cerrahpasa Medical 
Faculty from June 2010 to June 2016 was performed. The 
data were collected from the medical records. Patients’ age, 
cervical cytology results, colposcopy findings, histopatho- 
logy results of LEEP including number of specimens [one vs 
multiple], size of tissue, glandular involvement, and endo- 
and ectocervical surgical margin status, histopathology 
results of endocervical curettage, and follow-up cytology 
results were consulted. Women who had undergone cer-
vical biopsy under colposcopic examination before LEEP 
and those with incomplete medical records were excluded.
Women with cytological abnormalities or post-coital 
bleeding and women with suspicious macroscopic find-
ings on vaginal examination underwent colposcopy. An 
experienced gynecologic oncologist or a trained fellow of 
gynecologic oncology performed all examinations. A Carl 
Zeiss colposcope (Carl Zeiss. Oberkochen, Germany) with 
a magnification of between 4× and 20× was used for colpo- 
scopy. Subsequently, patients were offered the option of 
LEEP when CIN 2+ was suspected or colposcopic examina-
tion was inadequate. A 15 to 25 mm round loop electrode 
was used at 60 W aimed at excision of the transformation 
zone or the lesion. ECC was performed with a size 0 uter-
ine curette in all patients following LEEP. Hemostasis was 
obtained by cauterization of the surgical site using a ball 
electrode at a setting of 50 W. The pieces were fixed in 
formalin and sent for histopathologic evaluation. All of the 
LEEP and ECC procedures were performed by gynecologic 
oncology fellows or by trained physicians, supervised by 
gynecologic oncology fellows. All of the specimens were 
evaluated by the same pathologist (S.I.).
The cervical cytology results were classified in accord-
ance with the Bethesda System of 2001 [11]. The histological 
findings were described as negative, cervical intraepithelial 
lesion 1, CIN 2, CIN 3, adenocarcinoma in situ (AIS), or cancer. 
CIN 2+ was defined as CIN 2-3, AIS, and cancer. Overtreat-
ment was defined as having CIN 1 or a negative result on 
final histopathology.
Re-LEEP was offered to patients if positive surgical mar-
gin after LEEP or pre-invasive pathology at ECC was pre-
sent. After obtaining negative surgical margins, post-LEEP 
follow-up was every six months for one year by cervical 
cytology, and then annually if two subsequent normal cy-
tological results were obtained. Recurrence was defined as 
having ASCUS, LSIL, ASC-H, HSIL, or atypical glandular cells 
on cervical cytology during follow-up.
Statistical analyses were performed using Statistical 
Package for the Social Sciences (SPSS) version 16.0 (SPSS Inc., 
Chicago, IL, USA), while clinicopathological variables, includ-
ing the categorical data, were analyzed using the chi-square 
or Fisher’s exact test. All reported confidence interval (CI) 
values were calculated at the 95% level. A probability value 
of less than 0.05 was defined as statistically significant.
RESULTS
Clinicopathologic characteristics of the patients are pre-
sented in Table 1. The women had a mean age of 34.1 years, 
with a range of 19–68. LSIL and HSIL were the most common 
cytological anomalies managed with S & T. Additionally, 
17 women had a normal Pap smear result, 14 had post-coital 
Table 1. Clinicopathologic characteristics of study group
Mean (year) Range (year)
Age 34.1 19–68
n %
Pap smear 
Negative 17 2.1
ASCUS 130 16.2
LSIL 280 35.0
ASC-H 109 13.6
HSIL 244 30.5
AGC 20 2.5
Final histology
Negative 171 21.3
CIN I 202 25.2
CIN II 105 13.1
CIN III 302 37.7
AIS 2 0.2
Cancer 18 2.2
Total 800 100
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bleeding, and 3 had macroscopic cervical lesions. Thus, 
they underwent colposcopic examination and subsequent 
management with S & T. While pathological results of LEEP 
specimens were CIN 2+ in 427 out of 800 patients (53.3%), 
373 patients had CIN I or negative pathology, reflecting 
an overtreatment rate of 46.6%.
When histopathological results after LEEP were evalu-
ated per cytology results, 32.3%, 37.8%, 65.1%, 82.3%, and 
35% of women with ASCUS, LSIL, ASC-H, HSIL, and AGC 
cytology results, respectively, had CIN 2+ on final pathology 
(Table 2). The rate of CIN2+ lesion was 5.8% in women with 
normal cervical cytology. Cervical cancer was detected in 
four of 130 (3%) patients with ASCUS cytology. Furthermore, 
2.8% and 4.5% of patients with ASCH and HSIL cytology had 
cervical cancer after LEEP, respectively.
Overtreatment rates according to cytology results are 
presented in Table 3. No statistically significant relation was 
identified between unsatisfactory colposcopic examination 
Table 2. Histological results of LEEP specimens, according to cytology results
Histology
Pap smear
Negative
n (%)
ASCUS
n (%)
LSIL
n (%)
ASC-H
n (%)
HSIL
n (%)
AGC
n (%)
Negative 10 (58.8) 54 (41.5) 65 (23.2) 22 (20.1) 9 (3.6) 11 (55)
CIN I 6 (35.2) 34 (26.1) 110 (39.2) 16 (14.6) 34 (13.9) 2 (10)
CIN II+ 1 (5.8) 42 (32.3) 105 (37.5) 71 (65.1) 201 (82.4) 7 (35)
CIN II – 13 (10) 44 (15.7) 12 (11) 36 (14.7) –
CIN III 1 (5.8) 25 (19.2) 61 (21.7) 55 (50.4) 153 (62.7) 7 (35)
AIS – – – 1 (0.9) 1 (0.4) –
Cancer – 4 (3) – 3 (2.8) 11 (4.5) –
Total 17 (100) 130 (100) 280 (100) 109 (100) 244 (100) 20 (100)
Table 3. Possible risk factors for overtreatment in S & T
n Overtreatment (n = 373)n (%)
Proper treatment (n = 427)
n (%) p value
Colposcopy
NSSatisfactory 532 238 (44.7) 294 (55.2)
Unsatisfactory 268 135 (50.3) 133 (49.6)
Age (years)
< 0.0001≤ 45 618 263 (42.5) 355 (57.4)
> 45 182 110 (60.4) 72 (39.5)
Initial cytology
< 0.0001
Negative 17 16 (94.1) 1 (5.8)
ASCUS 130 88 (67.6) 42 (32.3)
LSIL 280 175 (62.5) 105 (37.5)
ASC-H 109 38 (34.8) 71 (65.1)
HSIL 244 43 (17.6) 201 (82.4)
AGC 20 13 (65) 7 (35)
Number of fragments of LEEP
NSSingle 680 323 (47.5) 357 (52.5)
Multiple 120 50 (41.6) 70 (58.3)
Glandular involvement
< 0.0001Negative 660 365 (55.3) 295 (44.7)
Positive 140 8 (5.7) 132 (94.3)
NS — not significant
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and overtreatment rate. However, age > 45, initial cytology, 
and glandular involvement were found to be significantly 
associated with overtreatment rate. 
Table 4 shows the factors related to positive surgical 
margin and ECC. Initial cytology result, histolopathology, 
and glandular involvement were associated with both sur-
gical margin and ECC positivity. Age more than 45 years 
was associated with ECC positivity, but not with surgical 
margin positivity. The more advanced the histopathology, 
the more increased risk of surgical margin on LEEP and ECC 
positivity (p < 0.0001, for both). The rates of positive margin 
were 6.4% and 43.3% in patients having CIN I and CIN III 
diseases, respectively. Only 0.4% of patients with CIN I had 
pre-invasive disease in the endocervix; however, the ratio 
was 9.5% for patients with CIN III. In the whole group, posi-
tive margin rate and ECC positivity were 22.3% and 5.3%, 
respectively. Out of 179 patients who had positive surgi-
cal margin, 90 had endocervical margin positivity, 45 had 
ectocervical margin positivity, and 44 had both endo- and 
ectocervical margin positivity.
Most of the patients were regularly followed-up (697 of 
800 patients; 87.1%). When 122 patients who had under-
gone re-LEEP because of surgical margin or ECC positivity 
were excluded, recurrence was observed in 24 of 575 pa-
tients (4.1%) within 31 months mean follow-up time.
DISCUSSION
In the present study, the rates of CIN II+ lesions were 32%, 
37%, 65%, and 82% in patients with ASCUS, LSIL, ASC-H, and 
HSIL cytology results, respectively. These high CIN II + lesion 
rates are not compatible with many studies. In their study, 
Cho et al. [12] found that 26 of 145 (18%) patients with low 
grade cervical smear had undergone S & T due to high grade 
colposcopic impression had CIN II+ in their final pathology. 
The only study including 58 ASC-H patients who had under-
gone S & T found a 72% rate of CIN II+ in their LEEP results [13]. 
CIN II+ rate was found to be between 65% and 90% in HSIL 
cytologies when managed according to S & T [14].
Increased high-grade lesion rates even in minimal ab-
normal cytology such as ASCUC and LSIL may be based on 
Table 4. Relationship between clinicopathologic factors and surgical margina
Surgical margin
p value
ECC
p value(+)
n (%)
(–)
n (%)
(+)
n (%) 
(–)
n (%)
Initial cytology
< 0.0001 < 0.0001
ASCUS 16 (12.3) 114 (87.6) 5 (3.8) 125 (96.1)
LSIL 35 (12.5) 245 (87.5) 5 (1.7) 275 (98.2)
ASC-H 28 (25.6) 81 (74.3) 7 (6.4) 102 (93.5)
HSIL 98 (40.1) 146 (59.8) 25 (20.4) 219 (79.5)
AGC 2 (10) 18 (90) 1 (5) 19 (95)
Colposcopy
NS NSSatisfactory 128 (29.6) 304 (70.3) 31 (7.1) 403 (92.8)
Unsatisfactory 51 (28.4) 146 (32.4) 12 (6) 185 (93.9)
Age (years)
NS < 0.0001≤ 45 141 (27.2) 375 (72.7) 21 (4) 495 (95.9)
> 45 38 (33.6) 75 (66.3) 22 (19.1) 93 (80.9)
Number of fragments of LEEP
NS NSSingle 145 (27) 391 (73) 33 (6.1) 505 (93.8)
Multiple 34 (36.5) 59 (63.5) 10 (10.7) 83 (89.3)
Histopathology
< 0.0001 < 0.0001CIN I 13 (6.4) 189 (93.5) 1 (0.4) 201 (99.5)
CIN II+ 166 (38.8) 261 (61.1) 42 (9.7) 387 (90.2)
Glandular involvement
< 0.0001 < 0.0001Negative 92 (18.6) 399 (81.3) 14 (2.8) 478 (97.1)
Positive 87 (63) 51 (36.9) 29 (20.8) 110 (79.1)
Total 179 450 43 588 
aOne hundred and seventy one women with negative histology were excluded from analysis. Two women had negative LEEP but positive ECC result. Finally, a total of 
629 and 631 women were analysed for surgical margin and ECC status, respectively; NS — not significant
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the management of these patients in a single gynecologic 
oncology clinic and the fact that many of the patients are re-
ferred from other clinics. With these findings, we can say that 
in contrast to the new recommendations of some societies, 
all women with ASCUS should be evaluated by colposcopic 
examination for the diagnosis of CIN II + lesion including 
cervical cancer [15].
The most problematic issue related to S & T is the high 
overtreatment rate of this approach for the management of 
the women who present with minimal abnormal cytology 
(ASCUS or LSIL) results. In this group of patients, the over-
treatment rate was found to be 65%. When S & T has been 
applied to patients with low grade cytology, the overtreat-
ment rate may rise up to 60% [16]. In a recent meta-analysis, 
the overtreatment rate was found to be 46% in patients 
with ASCUS or LSIL [14]. Overtreatment rates of S & T and 
three-step procedure in high grade abnormal cytologies are 
comparable considering the 11–35% rates of overtreatment 
of cervical biopsy under colposcopy followed by LEEP if the 
biopsy shows CIN 2+ [16, 17]. In addition, our findings are 
compatible with the recommendation of American Society 
for Colposcopy and Cervical Pathology, which states that it is 
acceptable to treat women with HGSIL cytology according to 
S & T, except those who are pregnant or aged 21–24 years [18]. 
In the meantime, considering the recommendation of the 
British Society for Colposcopy and Cervical Pathology, which 
states that overtreatment rate should be under 10%, S & T 
may be abandoned for low grade cytology [19]. According 
to the results of this present study, S & T does not make 
sense for patients with minimal abnormal cytology because 
of high overtreatment rate, but it is logical in the case of 
HSIL cytology. 
There are some factors that affect the overtreatment rate 
of S & T protocol. For example, Bosgraaf et al. [20] demon-
strated that women aged 40 years or more are more likely 
to be over-treated. Additionally, Kim YJ et al. [21] found that 
ASCUS and LSIL cytology are associated with higher rates 
of overtreatment in patients who undergo S & T. In our 
study, overtreatment was seen in only 6% of patients with 
glandular involvement. Also, in the advanced age group, 
overtreatment was much higher compared to the other 
group (< 45 years of age) in the study. The main reason for 
this is physicians prefer S & T rather than the three-step 
treatment for advanced age patients due to insufficient col-
poscopy results. Thus, postmenopausal patients should be 
selected more carefully for S & T. As glandular involvement 
can be determined at final pathology, it cannot be used for 
selection of patients for S & T. 
Positive surgical margin following LEEP has been shown to 
be associated with relapse or progression of the disease [10]. 
A meta-analysis of 35.100 patients with any grade of CIN 
or cervical cancer demonstrated a 23% rate of positive 
surgical margin following conization [22]. Age more than 
50 years, ECC positivity, gravidity > 2, high risk HPV load, 
and parity > 4 were demonstrated as significant factors for 
incomplete excision [23]. In our series, 22.3% of patients who 
had undergone LEEP for S & T had positive surgical margin. 
Our study demonstrated that the rate of surgical margin 
positivity gradually increases with the degree of abnor-
mality in the cervical smear. While almost 12% of patients 
with minimal cytological abnormality had positive surgical 
margin after LEEP, the ratio was 40% for patients with HSIL. 
Similarly, ECC positivity increased with the severity of abnor-
mal cytology. Twenty percent of patients with HSIL cytology 
had ECC positivity. In addition, we showed that glandular 
involvement increases the risk of surgical margin positivity 
as well as higher grade of abnormality. Consistent with our 
results, Ayhan et al. found that CIN 2+ on final pathology 
is associated with surgical margin positivity [24]. They also 
showed that the need for multiple sweeps during LEEP was 
the most important predictor of disease persistence [24]. We 
know that LEEP is associated with higher rates of positive 
surgical margin in lesions involving more than two-third 
of the cervix compared to cold-knife conization [25]. As 
an indicator of number of sweeps, the number of fragments 
of LEEP was not associated with surgical margin positivity 
in our study. One possible explanation for different results 
among both studies may be that a 15–20 mm round loop 
electrode was used in their study, while we used a 15 to 
25 mm round loop according to cervical dimension. From 
our point of view, use of larger loops or cold-knife excision 
may be helpful to provide clear surgical margins. 
In the present study, 179 of 629 patients with CIN I or 
higher in final pathology had surgical margin positivity 
(28.4%). In our clinic, re-LEEP is offered to patients with 
positive surgical margin or ECC. Regular follow-up for each 
six month period in the first year and then annually are 
performed for patients who have undergone LEEP. Even 
though 17% rate of recurrence was reported in patients 
with negative surgical margin after LEEP was performed, 
only 4% of our patients with no surgical margin involvement 
recurred within 31 months’ follow-up [3]. This low recurrence 
rate may be related to the short follow-up period.
The major strengths of our study are the large number 
of patients and the fact that the same gynecopathologists 
evaluated the LEEP specimens. The main limitations are its 
retrospective design and that Pap smears were evaluated 
by different pathologists within different pathology labora-
tories. These limitations may explain the high rate of cancer 
in ASCUS cytology.
In conclusion, our findings suggest that the see and treat 
strategy can be used in patients with high grade cytologic 
anomaly with an acceptable overtreatment rate, regardless 
of age. Patients with low grade cytologic abnormalities 
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should be counselled about high rates of overtreatment. 
S & T may be beneficial in those who are prone to dropout 
from treatment, especially in patients less than 45 years of 
age. In addition, bigger pieces of specimens may need to 
be removed during LEEP in patients who have suspicious 
images of higher grade abnormalities on colposcopy to 
reduce surgical margin or ECC positivity. Given the high rate 
of ECC positivity in patients with HSIL cytology, we suggest 
performing ECC on every patient with HSIL during LEEP.
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